Allergy Therapeutics Asset Resilience Ratio
Allergy Therapeutics asset resilience ratio. Allergy Therapeutics (AGY) has an Asset Resilience Ratio of 0.31% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Allergy Therapeutics to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Allergy Therapeutics (2007–2024)
Asset resilience ratio of Allergy Therapeutics from 2007 to 2024. This chart shows how Allergy Therapeutics's Asset Resilience Ratio has changed over time. Read Allergy Therapeutics total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Allergy Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AGY total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX200.00K | 0.31% |
| Total Liquid Assets | GBX200.00K | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Allergy Therapeutics maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Allergy Therapeutics Industry Peers by Asset Resilience Ratio
Compare Allergy Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Allergy Therapeutics Asset Resilience Ratio by Year (2007–2024)
Allergy Therapeutics asset resilience ratio by year from 2007 to 2024. The table below shows the annual Asset Resilience Ratio data for Allergy Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.31% | GBX200.00K ≈ $24.33 |
GBX64.83 Million ≈ $7.89K |
-0.40pp |
| 2017-06-30 | 0.71% | GBX404.00K ≈ $49.16 |
GBX57.18 Million ≈ $6.96K |
+18.93pp |
| 2016-06-30 | -18.23% | GBX-10.33 Million ≈ $-1.26K |
GBX56.68 Million ≈ $6.90K |
-19.77pp |
| 2015-06-30 | 1.54% | GBX783.00K ≈ $95.27 |
GBX50.70 Million ≈ $6.17K |
+0.33pp |
| 2014-06-30 | 1.21% | GBX345.00K ≈ $41.98 |
GBX28.40 Million ≈ $3.46K |
+1.21pp |
| 2013-06-30 | 0.01% | GBX2.00K ≈ $0.24 |
GBX28.96 Million ≈ $3.52K |
-1.73pp |
| 2012-06-30 | 1.74% | GBX483.00K ≈ $58.77 |
GBX27.75 Million ≈ $3.38K |
+1.73pp |
| 2008-06-30 | 0.01% | GBX3.00K ≈ $0.37 |
GBX23.18 Million ≈ $2.82K |
-0.25pp |
| 2007-06-30 | 0.26% | GBX63.00K ≈ $7.67 |
GBX23.99 Million ≈ $2.92K |
-- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more